Atopic Dermatitis NHP Model

Name: China Atopic Dermatitis NHP Model - Atopic Dermatitis NHP Model Research | PRISYS
Brand: Prisys
SKU: 259834933

Learn about Atopic Dermatitis (AD), a chronic inflammatory skin disease. Explore its causes, clinical implications, and the advantages of using non-human primate (NHP) models, particularly compared to mouse models, for AD research. Discover how NHP models offer valuable insights into human AD pathophysiology and potential therapeutic interventions.

Send Inquiry

Product Introduction

Atopic Dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus, erythema, and epidermal barrier dysfunction. It is a multifactorial disease involving genetic susceptibility, immune dysregulation, and environmental triggers. The global prevalence of AD is increasing, affecting up to 20% of children and 10% of adults, with significant impacts on quality of life and economic burden. AD pathogenesis involves complex interactions among keratinocytes, immune cells, and the microbiome, making it a challenging yet essential target for therapeutic research.

Cause:

The pathogenesis of AD is multifaceted:

Epidermal Barrier Dysfunction: Mutations in filaggrin (FLG) gene impair the barrier, increasing susceptibility to allergens and irritants.
Immune Dysregulation: Overactivation of type 2 immune responses, driven by cytokines such as IL-4, IL-13, IL-31, and IL-33, leads to inflammation and pruritus.
Microbiome Dysbiosis: Dominance of Staphylococcus aureus exacerbates inflammation and disrupts skin homeostasis.
Environmental Triggers: Allergens, pollutants, and stress contribute to disease exacerbation. These interconnected factors underscore the importance of holistic models to study AD pathogenesis and evaluate therapeutic interventions.

Advantages of Non-Human Primate (NHP) Models for Atopic Dermatitis Research:

1.Genetic and Physiological Similarity to Humans: NHPs share closer immune system and skin barrier architecture compared to rodents.

2.Relevance to Human Disease Mechanisms: NHPs exhibit natural immune responses and skin microbiome composition akin to humans, providing higher predictability for therapeutic outcomes.

3.Robust Clinical Signs: Symptoms such as erythema, scaling, and pruritus closely mirror human AD.

4.Simultaneous Atopic Disease Modeling: Prisys' AD NHP model allows for the concurrent induction of AD, allergic rhinitis, and asthma, offering a comprehensive platform for studying systemic atopic conditions.

Advantages of NHP Models Compared to Mouse Models for Atopic Dermatitis Research:

Higher Translational Value: NHPs better mimic human immune responses, providing more reliable data for therapeutic development.

Extended Study Duration: NHP models support chronic disease studies, enabling longitudinal assessments of treatments.

Integrated Multisystem Approach: Unlike mouse models, NHPs can simulate systemic atopic conditions such as asthma and allergic rhinitis alongside AD.

Detailed Behavioral Observations: NHPs display scratching and other behaviors that more closely resemble human symptoms, enhancing the evaluation of therapeutic efficacy.

Study design and clinical endpoints

Prisys Biotech's NHP AD model is meticulously designed to emulate human disease and provide actionable insights:

Study design：

•Sensitization using ovalbumin (OVA) with aluminum adjuvant via intraperitoneal, subcutaneous, or aerosol routes.

•Maintenance of disease phenotype through boosters and challenges tailored to mimic chronic AD progression.

•Validation through intracutaneous tests and observable clinical signs.

Clinical endpoints:

1.Clinical Scoring: Erythema, scaling, pruritus, and lesion severity (adapted from the EASI scale).

2.Histopathological Analysis: Evaluation of epidermal hyperplasia, inflammatory cell infiltration, and mast cell activity.

3.Biomarker Quantification: Levels of serum IgE, IL-4, IL-13, and IFN-γ.

4.Behavioral Observations: Pruritus frequency and severity.

5.Skin Microbiome Analysis: Profiling of microbial communities.

6.Pulmonary Function Tests: For cases of co-induced asthma, pulmonary responses to acetylcholine (ACh) are assessed.

Histological comparison between control and treated groups, highlighting reduced inflammatory markers.

key result and figure legend

Translational approach: PC50 test with acetylcholine (ACh)

Lung functions declined upon OVA inhalation after a successful sensitization

Hot Tags: atopic dermatitis nhp model, research, study, monkey, gene therapy, NHP Chronic Obstructive Pulmonary Disease Model, antibody PD pharmacology, Diabetes Non Human Primate Model, NHP DMPK pharmacology, nucleotide PD pharmacology, NHP Safety evaluation

Inflammatory Bowel Disease IBD NHP Model

Pruritus NHP Model